期刊
EMBO MOLECULAR MEDICINE
卷 11, 期 4, 页码 -出版社
WILEY
DOI: 10.15252/emmm.201809976
关键词
ADAM17; ERK MAPK; IL-6 trans-signaling; KRAS; lung adenocarcinoma
资金
- National Health and Medical Research Council (NHMRC) of Australia
- United States Department of Defense (Lung Cancer Research Program Idea Development Award)
- Victorian Government of Australia
- Deutsche Forschungsgemeinschaft (DFG) [CRC841, CRC877]
- Excellence Cluster 306 Inflammation at Interfaces
- DFG [SFB877]
- Department of Health \ National Health and Medical Research Council (NHMRC)
Oncogenic KRAS mutations are major drivers of lung adenocarcinoma (LAC), yet the direct therapeutic targeting of KRAS has been problematic. Here, we reveal an obligate requirement by oncogenic KRAS for the ADAM17 protease in LAC. In genetically engineered and xenograft (human cell line and patient-derived) Kras(G12D)-driven LAC models, the specific blockade of ADAM17, including with a non-toxic prodomain inhibitor, suppressed tumor burden by reducing cellular proliferation. The pro-tumorigenic activity of ADAM17 was dependent upon its threonine phosphorylation by p38 MAPK, along with the preferential shedding of the ADAM17 substrate, IL-6R, to release soluble IL-6R that drives IL-6 transsignaling via the ERK1/2 MAPK pathway. The requirement for ADAM17 in Kras(G12D)-driven LAC was independent of bone marrow-derived immune cells. Furthermore, in KRAS mutant human LAC, there was a significant positive correlation between augmented phospho-ADAM17 levels, observed primarily in epithelial rather than immune cells, and activation of ERK and p38 MAPK pathways. Collectively, these findings identify ADAM17 as a druggable target for oncogenic KRAS-driven LAC and provide the rationale to employ ADAM17-based therapeutic strategies for targeting KRAS mutant cancers.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据